)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
BenevolentAI société anonyme
BenevolentAI société anonyme (BAI) investor relations material
BenevolentAI société anonyme has been delisted
BenevolentAI société anonyme H1 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2024 earnings summary19 Sep, 2024
Executive summary
Strengthened leadership and board with new Chair, Deputy Chair, CEO, CTO, and business development focus, driving innovation and execution.
Positive topline Phase I data for lead asset BEN-8744 in ulcerative colitis/inflammatory bowel disease, with full data to be presented at a major conference.
Expanded and productive collaborations with AstraZeneca and Merck KGaA, with new targets, milestones, and validation of the AI platform.
Business development pipeline for collaborations and out-licensing has grown, though deal timing remains uncertain.
Cash runway extended to late Q3 2025, supporting ongoing R&D and business development activities.
Financial highlights
Operating loss reduced by 30% to £32.3m in H1 2024 from £45.9m in H1 2023, reflecting restructuring and R&D prioritization.
Revenue decreased 46% to £2.8m, mainly due to transition between AstraZeneca and Merck collaborations.
R&D spend reduced by 45% to £19.9m, focusing on proprietary pipeline and platform innovation.
Cash and equivalents at £38.1m as of 30 June 2024, with runway extended to late Q3 2025, including £12.1m R&D tax credits received post-period.
Basic and diluted EPS improved to (20.3p); normalised EPS (18.4p).
Outlook and guidance
Additional Merck collaboration revenue expected in H2 2024 through 2026 as milestones are achieved.
Ongoing active licensing and collaboration discussions, with a focus on value inflection points for pipeline assets.
Cash runway extends to late Q3 2025, excluding unsigned revenue; further cost-saving actions available if needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
BenevolentAI société anonyme
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BenevolentAI société anonyme is active in the pharmaceutical industry, specializing in AI-enabled drug discovery. The company's core mission revolves around integrating artificial intelligence (AI) with advanced scientific research to innovate and develop new medications for complex diseases. It leverages its proprietary Benevolent Platform, an AI-driven drug discovery engine that utilizes a vast biomedical data landscape to offer a comprehensive representation of human biology across various diseases. This platform aids both in-house scientists and biopharmaceutical partners in accelerating scientific breakthroughs by harnessing the full potential of data and AI for the next generation of medical advancements. The company is headquartered in Luxembourg and its shares are listed on the Euronext Amsterdam stock exchange.